Literature DB >> 18414393

Standard antiepileptic drugs fail to block epileptiform activity in rat organotypic hippocampal slice cultures.

K Albus1, A Wahab, U Heinemann.   

Abstract

BACKGROUND AND
PURPOSE: Earlier studies had demonstrated that tonic-clonic seizure-like events (SLEs) resembling electrographic correlates of limbic seizures in animals and humans can be induced in organotypic hippocampal slice cultures (OHSCs). We have explored OHSCs for their suitability to serve as in vitro models of limbic seizures for studying seizure mechanisms and screening new antiepileptic compounds. EXPERIMENTAL APPROACH: OHSCs were cultivated according to the interface method. Neuronal activity and extracellular potassium concentration were recorded under submerged conditions. SLEs were induced by lowering magnesium concentration or by applying the potassium channel blocker 4-aminopyridine. The effects of standard antiepileptic drugs (AEDs), carbamazepine, phenytoin, valproic acid, clonazepam, diazepam and phenobarbital sodium on SLEs were analysed. KEY
RESULTS: In more than 93% of OHSCs, AEDs did not prevent the induction of SLEs or stop ongoing seizure activity even when toxic concentrations were applied. This pharmacoresistance was independent of the method of seizure provocation, postnatal age at explantation (P2-P10) and cultivation time in vitro (2 months). SLEs were reversibly blocked by glutamate antagonists or the GABA(A)-agonist muscimol. CONCLUSIONS AND IMPLICATIONS: We present a simple to establish in vitro model of tonic-clonic SLEs that is a priori pharmacoresistant and thus has an advantage over animal models of pharmacoresistant seizures in which responders and non-responders can be sorted out only after an experiment. OHSCs could be suitable for exploring mechanisms of pharmacoresistant seizures and be used for the identification of new anticonvulsive compounds eventually effective in drug refractory epilepsy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18414393      PMCID: PMC2439516          DOI: 10.1038/bjp.2008.112

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  97 in total

Review 1.  Cellular and molecular mechanisms of epilepsy in the human brain.

Authors:  Massimo Avoli; Jacques Louvel; René Pumain; Rüdiger Köhling
Journal:  Prog Neurobiol       Date:  2005-10       Impact factor: 11.685

Review 2.  Pediatric epilepsy models.

Authors:  Frances E Jensen
Journal:  Epilepsy Res       Date:  2006-01       Impact factor: 3.045

3.  Treating refractory epilepsy in adults.

Authors:  Edward Reynolds
Journal:  BMJ       Date:  2006-03-11

4.  Epileptiform activity induced by pharmacologic reduction of M-current in the developing hippocampus in vitro.

Authors:  Fernando Peña; Noé Alavez-Pérez
Journal:  Epilepsia       Date:  2006-01       Impact factor: 5.864

5.  Antiepileptic drug-resistant rats differ from drug-responsive rats in hippocampal neurodegeneration and GABA(A) receptor ligand binding in a model of temporal lobe epilepsy.

Authors:  Holger A Volk; Dimitrula Arabadzisz; Jean-Marc Fritschy; Claudia Brandt; Kerstin Bethmann; Wolfgang Löscher
Journal:  Neurobiol Dis       Date:  2005-10-26       Impact factor: 5.996

6.  Vascular colocalization of P-glycoprotein, multidrug-resistance associated protein 1, breast cancer resistance protein and major vault protein in human epileptogenic pathologies.

Authors:  S M Sisodiya; L Martinian; G L Scheffer; P van der Valk; R J Scheper; B N Harding; M Thom
Journal:  Neuropathol Appl Neurobiol       Date:  2006-02       Impact factor: 8.090

Review 7.  Molecular and cellular mechanisms of pharmacoresistance in epilepsy.

Authors:  Stefan Remy; Heinz Beck
Journal:  Brain       Date:  2005-11-29       Impact factor: 13.501

Review 8.  Drug resistance in epilepsy: putative neurobiologic and clinical mechanisms.

Authors:  Dieter Schmidt; Wolfgang Löscher
Journal:  Epilepsia       Date:  2005-06       Impact factor: 5.864

Review 9.  Drug resistance in brain diseases and the role of drug efflux transporters.

Authors:  Wolfgang Löscher; Heidrun Potschka
Journal:  Nat Rev Neurosci       Date:  2005-08       Impact factor: 34.870

10.  NKCC1 transporter facilitates seizures in the developing brain.

Authors:  Volodymyr I Dzhala; Delia M Talos; Dan A Sdrulla; Audrey C Brumback; Gregory C Mathews; Timothy A Benke; Eric Delpire; Frances E Jensen; Kevin J Staley
Journal:  Nat Med       Date:  2005-10-09       Impact factor: 53.440

View more
  17 in total

1.  Magnolol, a major bioactive constituent of the bark of Magnolia officinalis, exerts antiepileptic effects via the GABA/benzodiazepine receptor complex in mice.

Authors:  C R Chen; R Tan; W M Qu; Z Wu; Y Wang; Y Urade; Z L Huang
Journal:  Br J Pharmacol       Date:  2011-11       Impact factor: 8.739

2.  An organotypic hippocampal slice culture model of excitotoxic injury induced spontaneous recurrent epileptiform discharges.

Authors:  Julie M Ziobro; Laxmikant S Deshpande; Robert J Delorenzo
Journal:  Brain Res       Date:  2010-11-25       Impact factor: 3.252

3.  Excitatory GABAergic signalling is associated with benzodiazepine resistance in status epilepticus.

Authors:  Richard J Burman; Joshua S Selfe; John Hamin Lee; Maurits van den Berg; Alexandru Calin; Neela K Codadu; Rebecca Wright; Sarah E Newey; R Ryley Parrish; Arieh A Katz; Jo M Wilmshurst; Colin J Akerman; Andrew J Trevelyan; Joseph V Raimondo
Journal:  Brain       Date:  2019-11-01       Impact factor: 13.501

4.  DREADDs suppress seizure-like activity in a mouse model of pharmacoresistant epileptic brain tissue.

Authors:  N Avaliani; M Andersson; A H Runegaard; D Woldbye; M Kokaia
Journal:  Gene Ther       Date:  2016-07-14       Impact factor: 5.250

5.  Surface charge impact in low-magnesium model of seizure in rat hippocampus.

Authors:  Dmytro Isaev; Gleb Ivanchick; Volodymyr Khmyz; Elena Isaeva; Alina Savrasova; Oleg Krishtal; Gregory L Holmes; Oleksandr Maximyuk
Journal:  J Neurophysiol       Date:  2011-10-26       Impact factor: 2.714

Review 6.  Issues related to development of new antiseizure treatments.

Authors:  Karen S Wilcox; Tracy Dixon-Salazar; Graeme J Sills; Elinor Ben-Menachem; H Steve White; Roger J Porter; Marc A Dichter; Solomon L Moshé; Jeffrey L Noebels; Michael D Privitera; Michael A Rogawski
Journal:  Epilepsia       Date:  2013-08       Impact factor: 5.864

7.  Seizures as imbalanced up states: excitatory and inhibitory conductances during seizure-like events.

Authors:  Jokubas Žiburkus; John R Cressman; Steven J Schiff
Journal:  J Neurophysiol       Date:  2012-12-05       Impact factor: 2.714

Review 8.  Possible alterations in GABAA receptor signaling that underlie benzodiazepine-resistant seizures.

Authors:  Tarek Z Deeb; Jamie Maguire; Stephen J Moss
Journal:  Epilepsia       Date:  2012-12       Impact factor: 5.864

Review 9.  How might novel technologies such as optogenetics lead to better treatments in epilepsy?

Authors:  Esther Krook-Magnuson; Marco Ledri; Ivan Soltesz; Merab Kokaia
Journal:  Adv Exp Med Biol       Date:  2014       Impact factor: 2.622

10.  Optogenetic control of epileptiform activity.

Authors:  Jan Tønnesen; Andreas T Sørensen; Karl Deisseroth; Cecilia Lundberg; Merab Kokaia
Journal:  Proc Natl Acad Sci U S A       Date:  2009-07-06       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.